Home > Boards > US OTC > Biotechs > BELLUS Health Inc. (BLUSF)

today announced the completion of the KIACTA™ (eprodisate)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
xr_biotech_consult Member Profile
 
Followed By 15
Posts 1,039
Boards Moderated 0
Alias Born 03/12/10
160x600 placeholder
xr_biotech_consult   Thursday, 01/21/16 08:36:40 AM
Re: BioSpecialist post# 237
Post # of 258 
today announced the completion of the KIACTA™ (eprodisate) Phase 3 confirmatory study for the treatment of AA amyloidosis. Top-line results are expected to be announced in Q2 2016 after all remaining patients have completed final study visits, all queries have been resolved based on input from study sites and the database has been locked.
http://ih.advfn.com/p.php?pid=nmona&article=70080770

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist